Women aged 40 and older with node-positive early breast cancer, a group traditionally routed straight to chemotherapy, may ...

Persistent outcome disparities, particularly worse prognoses for Black women with breast cancer, persist even within the same genomic risk categories. Effective management requires integrating genomic ...

MARLBOROUGH, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, today announced the availability of a new assay designed to advance ...

Spatial biology has emerged as a highly valuable field of study, examining the relationships between biological cells and molecules in their native spatial orientation, which can occur in both ...

Multicancer early detection (MCED) assays use circulating tumor DNA, methylation patterns, RNA, and protein biomarkers to detect multiple cancer types early, potentially revolutionizing cancer ...

RxDx Assay fulfils an unmet medical need by helping clinicians identify patients with PTEN protein loss who may benefit from combination treatment with TRUQAPIn prostate cancer, PTEN protein loss is a ...

Functional Characterization and a Real-World Clinical Laboratory Pilot of the Foundation for the National Institutes of Health Circulating Tumor DNA Quality Control Materials A total of 871 patient ...

The shift towards utilizing complex organ-like structures developed from stem cells or tissue samples is becoming essential; these organoid models are leading the way to next-generation, animal-free ...

Friends of Cancer Research initiated a research partnership, inviting HRD assay developers to participate in two blinded analyses. In the first, 11 assay developers reported HRD status for the Cancer ...

(RTTNews) - Akoya Biosciences, Inc. (AKYA), Thursday announced the launch of a new multiplex immunofluorescence or mIF assay to advance antibody-drug conjugate or ADC development in breast cancer, ...